"Unlucky year"! Corning Jerry has yet another critical clinical failure. How much longer until the next product is launched?

①For the overseas key experiment of KN035 in soft tissue sarcoma, the objective response rate of patients can be evaluated as 5%, which is lower than the required 11% for supporting biological product license application; ②With only the commercialization of KN035, several key clinical trials of KN046 have encountered setbacks previously, which further delayed the market launch of the new product by Conagen.

cls.cnJul 4 18:05

Kn Hospital (02120.HK) saw a 15.2% increase in inpatient bed days in the first half of the year, while daily total spending fell by 7.8%.

KN Hospital (02120.HK) announced that in the second quarter ending in June, there were 955,400 hospital bed days, an increase of 14.1% annually; the total average daily expenditure per bed day for inpatients was 370 yuan RMB, a decrease of 4.9%. The number of outpatient visits was 122,200, a decrease of 3%; the total average expenditure per outpatient visit was 437 yuan, a decrease of 1.8%.

AASTOCKSJul 4 00:49

Corning Is Maintained at Hold by Deutsche Bank

Corning Is Maintained at Hold by Deutsche Bank

Dow JonesJul 3 20:00

Corning Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 1.59% Deutsche Bank $35 → $39 Maintains Hold 06/21/2024 17.22% Citigroup $38 → $45 Maintains Bu

BenzingaJul 3 19:49

Deutsche Numis Maintains Corning(GLW.US) With Hold Rating, Raises Target Price to $39

Deutsche Numis analyst Matthew Niknam maintains $Corning(GLW.US)$ with a hold rating, and adjusts the target price from $35 to $39.According to TipRanks data, the analyst has a success rate of 53.9% a

Futu NewsJul 3 19:31 · Ratings

Balancing Growth Prospects With Valuation Concerns: A Hold Rating for Corning

TipRanksJul 3 19:25